Trial ID or NCT#





This study was about IgA nephropathy, a form of kidney disease characterized by the presence of blood and protein in the urine. This study was done to determine if the medication rituximab could reduce protein in the patient's urine. Hypothesis: In patients with progressive IgA nephropathy an intravenous infusion of 1000 mg of rituximab on Day 1 and Day 15 and Days 168 and 182 is superior to conventional therapy in reducing 24 hour proteinuria, and slowing progression of chronic kidney disease.

Official Title

A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy

Eligibility Criteria

Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Richard Lafayette
Professor of Medicine (Nephrology) at the Stanford University Medical Center
Glenn M. Chertow
Professor of Medicine (Nephrology) and, by courtesy, of Health Research and Policy (Epidemiology)

Contact us to find out if this trial is right for you.


Richard Lafayette, MD
(650) 736-1822